The Proteomics Big Challenge for Biomarkers and New Drug-Targets Discovery

In the modern process of drug discovery, clinical, functional and chemical proteomics can converge and integrate synergies. Functional proteomics explores and elucidates the components of pathways and their interactions which, when deregulated, lead to a disease condition. This knowledge allows the...

Full description

Bibliographic Details
Main Authors:	Savino, Rocco, Paduano, Sergio, Preianò, Mariaimmacolata, Terracciano, Rosa
Format:	Online
Language:	English
Published:	Molecular Diversity Preservation International (MDPI) 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509558/

id	pubmed-3509558
recordtype	oai_dc
spelling	pubmed-35095582013-01-09 The Proteomics Big Challenge for Biomarkers and New Drug-Targets Discovery Savino, Rocco Paduano, Sergio Preianò, Mariaimmacolata Terracciano, Rosa Review In the modern process of drug discovery, clinical, functional and chemical proteomics can converge and integrate synergies. Functional proteomics explores and elucidates the components of pathways and their interactions which, when deregulated, lead to a disease condition. This knowledge allows the design of strategies to target multiple pathways with combinations of pathway-specific drugs, which might increase chances of success and reduce the occurrence of drug resistance. Chemical proteomics, by analyzing the drug interactome, strongly contributes to accelerate the process of new druggable targets discovery. In the research area of clinical proteomics, proteome and peptidome mass spectrometry-profiling of human bodily fluid (plasma, serum, urine and so on), as well as of tissue and of cells, represents a promising tool for novel biomarker and eventually new druggable targets discovery. In the present review we provide a survey of current strategies of functional, chemical and clinical proteomics. Major issues will be presented for proteomic technologies used for the discovery of biomarkers for early disease diagnosis and identification of new drug targets. Molecular Diversity Preservation International (MDPI) 2012-10-29 /pmc/articles/PMC3509558/ /pubmed/23203042 http://dx.doi.org/10.3390/ijms131113926 Text en © 2012 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0).
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Savino, Rocco Paduano, Sergio Preianò, Mariaimmacolata Terracciano, Rosa
spellingShingle	Savino, Rocco Paduano, Sergio Preianò, Mariaimmacolata Terracciano, Rosa The Proteomics Big Challenge for Biomarkers and New Drug-Targets Discovery
author_facet	Savino, Rocco Paduano, Sergio Preianò, Mariaimmacolata Terracciano, Rosa
author_sort	Savino, Rocco
title	The Proteomics Big Challenge for Biomarkers and New Drug-Targets Discovery
title_short	The Proteomics Big Challenge for Biomarkers and New Drug-Targets Discovery
title_full	The Proteomics Big Challenge for Biomarkers and New Drug-Targets Discovery
title_fullStr	The Proteomics Big Challenge for Biomarkers and New Drug-Targets Discovery
title_full_unstemmed	The Proteomics Big Challenge for Biomarkers and New Drug-Targets Discovery
title_sort	proteomics big challenge for biomarkers and new drug-targets discovery
description	In the modern process of drug discovery, clinical, functional and chemical proteomics can converge and integrate synergies. Functional proteomics explores and elucidates the components of pathways and their interactions which, when deregulated, lead to a disease condition. This knowledge allows the design of strategies to target multiple pathways with combinations of pathway-specific drugs, which might increase chances of success and reduce the occurrence of drug resistance. Chemical proteomics, by analyzing the drug interactome, strongly contributes to accelerate the process of new druggable targets discovery. In the research area of clinical proteomics, proteome and peptidome mass spectrometry-profiling of human bodily fluid (plasma, serum, urine and so on), as well as of tissue and of cells, represents a promising tool for novel biomarker and eventually new druggable targets discovery. In the present review we provide a survey of current strategies of functional, chemical and clinical proteomics. Major issues will be presented for proteomic technologies used for the discovery of biomarkers for early disease diagnosis and identification of new drug targets.
publisher	Molecular Diversity Preservation International (MDPI)
publishDate	2012
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509558/
_version_	1611936418883436544

The Proteomics Big Challenge for Biomarkers and New Drug-Targets Discovery

Similar Items